CD274 and gastric carcinoma: In a phase 1b clinical trial (KEYNOTE-012 study) conducted to assess pembrolizumab, 8 out of 36 patients (22.2%) with PD-L1-positive gastric carcinoma or gastroesophageal junction cancer were judged to have a partial response.